Algorae Expands AI Drug Combination Pipeline
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The program has generated a significant number of in silico synergy predictions across various drug combinations, enhancing the company's research capabilities. Initial filtering has identified a large number of synergy predictions, with a focus on prioritizing the strongest candidates for further evaluation. The company plans to collaborate with the Peter MacCallum Cancer Centre for independent validation of shortlisted candidates from this expanded pipeline.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- 1AI Executes License & Supply Agreement with Torrent Pharma
- Algorae and Zydus Enter Exclusive Commercial Agreement
- Algorae Pharmaceuticals Ltd Raises $3.9m
- TGA Accepts Initial Registration Dossier for Evaluation
- Peter Mac Partners with Algorae on AI Validation
Later from Algorae Pharmaceuticals
- Algorae Awarded NSW Health Public Hospital Supply Contract
- Updated - NSW Health Public Hospital Supply Contract
- Peter Mac Testing Validates AlgoraeOS v2
- Quarterly Activities Report/Appendix 4C Cashflow Statement
- Appendix 4E and 2026 Annual Report
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals